CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues
Product sales	$ 2,695.0	$ 1,994.1	$ 4,841.9	$ 3,845.2
Other revenues	37.4	47.0	81.4	82.1
Total revenues	2,732.4	2,041.1	4,923.3	3,927.3
Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	669.9	569.6	1,230.3	1,073.7
Cost of other revenues	15.2	16.0	29.5	30.3
Selling, general and administrative	685.5	515.7	1,259.3	997.7
Research and development	81.1	66.5	136.9	127.8
Amortization and impairments of finite-lived intangible assets	585.4	365.6	950.6	720.8
Restructuring, integration and other costs	143.4	142.1	198.4	275.7
In-process research and development impairments and other charges	12.3	8.4	12.3	20.4
Acquisition-related costs	9.5	0.6	19.3	2.1
Acquisition-related contingent consideration	11.7	1.9	18.8	10.8
Other expense (income)	176.9	(0.4)	183.0	(43.7)
Total expenses	2,390.9	1,686.0	4,038.4	3,215.6
Operating income	341.5	355.1	884.9	711.7
Interest income	0.9	1.2	1.8	3.0
Interest expense	(412.7)	(241.2)	(710.5)	(487.7)
Loss on extinguishment of debt	0.0	0.0	(20.0)	(93.7)
Foreign exchange and other	5.6	3.4	(65.5)	(10.0)
Gain on investments, net	0.0	2.5	0.0	2.5
(Loss) income before (recovery of) provision for income taxes	(64.7)	121.0	90.7	125.8
(Recovery of) provision for income taxes	(13.1)	(1.0)	67.8	24.1
Net (loss) income	(51.6)	122.0	22.9	101.7
Less: Net income (loss) attributable to noncontrolling interest	1.4	(3.8)	2.2	(1.5)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (53.0)	$ 125.8	$ 20.7	$ 103.2
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)	$ (0.15)	$ 0.38	$ 0.06	$ 0.31
Diluted (in usd per share)	$ (0.15)	$ 0.37	$ 0.06	$ 0.30
Weighted-average common shares (in millions)
Basic (in shares)	344.4	335.3	340.5	335.1
Diluted (in shares)	344.4	341.3	347.1	341.4